DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
56	ベーチェット病	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00664599 (ClinicalTrials.gov)	April 2006	20/4/2008	Rituximab for the Treatment of Severe Ocular Manifestations of Behcet's Disease	Effect of Rituximab in the Treatment of Resistant Ocular Inflammatory Lesions of Behcet's Disease (Pilot Study)	Behcet's Syndrome	Drug: Rituximab;Drug: Cytotoxic Combination	Tehran University of Medical Sciences	Hoffmann-La Roche	Completed	16 Years	N/A	Both	20	Phase 2	Iran, Islamic Republic of

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

April 2006

20/4/2008

Rituximab for the Treatment of Severe Ocular Manifestations of Behcet's Disease

Effect of Rituximab in the Treatment of Resistant Ocular Inflammatory Lesions of Behcet's Disease (Pilot Study)

Behcet's Syndrome

Drug: Rituximab;Drug: Cytotoxic Combination

Tehran University of Medical Sciences

Hoffmann-La Roche

Completed

16 Years

N/A

Both

Phase 2

Iran, Islamic Republic of